Jeil Pharmaceutical제일약품

Jeil Pharmaceutical's profit has recovered to a thin positive level after losses in 2024, while its share price has fallen sharply over the past year.

Jeil Pharmaceutical is a Korean pharma maker whose trailing twelve-month revenue is about ₩543B, with a small operating profit of about ₩3.7B and net income of about ₩9.3B through H1 2026. Revenue has been shrinking, falling 19.5% in 2025, and free cash flow is negative at about -₩15.8B. The shares closed at ₩9,190 on 21 October 2026, down 37.1% over one year and near the lower end of their 52-week range.

What stands out

• Trailing net income of about ₩9.3B is well above operating income of about ₩3.7B, so the profit figure is likely helped by items below the operating line; the data does not explain what they are.
• 2025 was a better year than 2024, with operating income of about ₩20.7B versus a loss of about ₩18.9B, but revenue fell 19.5% in 2025.
• Borrowings of about ₩110B exceed cash of about ₩59B, and liabilities are about 108% of equity.
• Foreign ownership fell from 1.9% to 1.1% over the past 60 days, and foreign investors were net sellers over the last 20 days.
• The data contains no recent news headlines, so the filings list is the main recent source of information.

What to watch

• The full-year 2026 results and the next quarterly report, to see whether the operating margin holds above zero.
• Whether free cash flow turns positive given the negative trailing figure and the debt load.
• The company's dividend stance, since the data shows no dividend yield at present.